Latest studies
Every paper our editors flag with a plain-language note and an evidence rating. Filter by evidence, species, or design to find what actually applies to you.
- Study · GHK-CuSupported
A tea exosome-integrated self‑oxygenating cascade chitosan/oxidized alginate hydrogel for remodeling the hyperglycemic and hypoxic microenvironment in diabetic wound healing.
GHK-Cu here is one gear in a clever multi-part system — its catalytic role converting hydrogen peroxide to oxygen — rather than the study's headline agent, so this is a materials-science signal more than a peptide-efficacy one. The wound-repair results are preclinical only, in cells and animal models. Still, it adds to a steady stream of work embedding GHK-Cu into wound-dressing platforms for its copper-redox chemistry and regenerative reputation, which is exactly the context our GHK-Cu readers track. File under early but credible platform research.
Carbohydrate polymersn=—AnimalOct 1, 2026 - Study · GHK-CuWeak / none
Microenvironment-responsive injectable dynamic hydrogel for sequential antioxidant and tissue regeneration therapy of radiation-induced skin injury.
This is a biomaterials study, tested in cells and in animals, in which GHK-Cu is one component of an engineered injectable hydrogel built to manage radiation-induced skin injury. The design is a two-stage system: superoxide-dismutase-mimicking carbon dots release first in the acidic wound to mop up reactive oxygen species, then GHK-Cu releases more slowly to support tissue repair. The researchers report the hydrogel reduced oxidative damage and inflammation and sped skin-wound closure in their in-vitro and in-vivo tests. Two things to keep in mind. First, GHK-Cu's contribution cannot be isolated from the carbon dots and the chitosan-hyaluronic-acid matrix - this is a combination system, so any benefit belongs to the platform, not the peptide alone. Second, these are preclinical results; human data would be needed before clinical conclusions could be drawn. For GHK-Cu specifically, this aligns with its established topical/local wound-repair and anti-inflammatory profile, but adds no human evidence for systemic use.
Bioactive materialsn=—AnimalSep 1, 2026 - Study · TB-500Mixed
Peptides in Regenerative Medicine: A Comprehensive Review of Clinical Applications in Tissue Repair and Chronic Pain Management.
A narrative review rather than new data, and the authors are explicit that the human evidence base for these peptides remains limited and largely preclinical. It is useful mainly as a map of proposed mechanisms and regulatory status for BPC-157, TB-500 and GHK-Cu in one place. Narrative reviews carry no systematic search or risk-of-bias assessment, so read the enthusiasm in the framing with that limit in mind. Regulatory status is unchanged: these remain unapproved for the indications discussed.
Current pain and headache reportsn=——Aug 24, 2026 - Study · GHK-CuMixed
The Regenerative Potential of GHK-Cu in Aesthetic Medicine.
The mechanistic case for GHK-Cu is unusually well developed for a cosmetic peptide, but the clinical base is two trials against 18 preclinical papers, and formulations, doses, and delivery methods vary widely between them. That imbalance is the story: readers should regard the collagen and matrix findings as biologically plausible and the human effect sizes as provisional. Anyone comparing topical products will find the delivery-system data more decision-relevant than the peptide concentration on the label.
Aesthetic surgery journaln=——Aug 20, 2026 - Study · TB-500Weak / none
Peptide Supplements and Their Therapeutic Applications in Sports Medicine.
This is the most direct literature audit yet of the peptides that dominate recovery marketing, and its finding is a familiar one: the animal work is interesting, the human work is thin. Sixty-seven percent of the included publications were preclinical, and the clinical studies that exist are heterogeneous in dose and route of administration. Worth citing on our BPC-157, TB-500, CJC-1295, ipamorelin and GHK-Cu pages as the current state of evidence, alongside the cardiovascular and metabolic risks the authors document.
The American journal of sports medicinen=——Aug 11, 2026 - Study · GHK-CuWeak / none
Copper peptide activated cascade catalysis for glucose regulation and hypoxia reversing in infected diabetic wound healing.
This preclinical materials study builds a glucose-oxidase-loaded hydrogel incorporating the copper tripeptide GHK-Cu for infected diabetic wounds via a two-step (cascade) reaction: glucose oxidase lowers local glucose and makes hydrogen peroxide, then copper from GHK-Cu breaks that peroxide down to release oxygen and relieve wound low-oxygen conditions, while GHK-Cu's own activity supports skin repair. Researchers reported the hydrogel showed antibacterial activity, promoted tissue repair, antioxidant capacity and new blood-vessel formation. These are laboratory and animal-model findings, mechanistic and formulation signals, not clinical evidence, and GHK-Cu is one functional component of a composite system rather than tested alone. This is a genuine (not sensor-analyte) use of GHK-Cu, relevant to its skin-repair evidence base, but human data would be needed before any clinical conclusion.
Materials today. Bion=—AnimalAug 1, 2026 - Study · GHK-CuWeak / none
Hierarchical regulation and mechanism of "open-hollow-fibrous network" structures: Osteogenic-angiogenic coupling responses of poly(γ-benzyl-L-glutamate) microspheres.
This is a materials-science and cell-culture (in-vitro) study, not a clinical investigation of GHK-Cu as an injectable peptide. GHK-Cu appears here as a bioactive coating chemically grafted onto porous polypeptide microspheres designed as scaffolds for bone repair. The researchers report that the copper-peptide-functionalised microspheres were cytocompatible and, compared with plain microspheres, increased mineralisation in bone-marrow mesenchymal stem cells and raised osteogenic gene expression (Runx2, OPN, and OCN by roughly 1.6- to 3.5-fold), alongside signs of blood-vessel formation in a tube-formation assay. Those are coherent signals consistent with copper's known role in matrix and vascular biology, but they are cell-level readouts in an engineered material - not evidence that GHK-Cu builds bone in a living body, still less in humans. These are preclinical findings; human data would be needed before clinical conclusions could be drawn. Weight this as scaffold-engineering proof-of-concept where the peptide is one functional ingredient among several.
Biomaterials advancesn=—In vitroJun 15, 2026